OVID THERAPEUTICS INC.Stock Option Agreement • April 10th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (the “Option Agreement”).
OVID THERAPEUTICS INC.Stock Option Agreement • April 10th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement — Early Exercise (the “Option Agreement”).
OVID THERAPEUTICS INC.Restricted Stock Purchase Agreement • April 10th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Unless otherwise defined herein, the terms defined in the 2014 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Restricted Stock Purchase Agreement (the “Agreement”).
LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND OVID THERAPEUTICS INC. JANUARY 6, 2017License and Collaboration Agreement • April 10th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is made effective as of January 6, 2017 (the “Effective Date”) by and between Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”) and Ovid Therapeutics Inc., a company incorporated under the laws of the State of Delaware having its principal place of business at 1460 Broadway, New York, NY 10036, U.S.A. (“Ovid”). Ovid and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • April 10th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
THIS SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 6th day of January, 2017 by and among Ovid Therapeutics Inc., a Delaware corporation (the “Company”), and Takeda Pharmaceutical Company Limited (the “Purchaser”).
